These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15217530)

  • 21. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
    Kim YH; Mio T; Mishima M
    Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib (Iressa) trials in non-small cell lung cancer.
    Johnson DH
    Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    Takano T; Ohe Y; Sakamoto H; Tsuta K; Matsuno Y; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Shibata T; Sakiyama T; Yoshida T; Tamura T
    J Clin Oncol; 2005 Oct; 23(28):6829-37. PubMed ID: 15998907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
    Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives.
    Adamo V; Franchina T; Adamo B; Denaro N; Gambadauro P; Chiofalo G; Scimone A; Caristi N; Russo A; Giordano A
    Cancer Biol Ther; 2009 Feb; 8(3):206-12. PubMed ID: 19182534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
    Pao W; Miller VA; Venkatraman E; Kris MG
    J Natl Cancer Inst; 2004 Aug; 96(15):1117-9. PubMed ID: 15292378
    [No Abstract]   [Full Text] [Related]  

  • 31. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
    Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
    Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
    Shih JY; Gow CH; Yu CJ; Yang CH; Chang YL; Tsai MF; Hsu YC; Chen KY; Su WP; Yang PC
    Int J Cancer; 2006 Feb; 118(4):963-9. PubMed ID: 16152581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 35. Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
    Gazdar AF
    Medicine (Baltimore); 2011 May; 90(3):168-170. PubMed ID: 21512415
    [No Abstract]   [Full Text] [Related]  

  • 36. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
    Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
    Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of gefitinib in the management of Asian patients with non-small cell lung cancer.
    Chang AY
    Expert Opin Investig Drugs; 2008 Mar; 17(3):401-11. PubMed ID: 18321238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
    Vansteenkiste J; Wauters E
    Ann Oncol; 2018 Jan; 29(suppl_1):i1-i2. PubMed ID: 29462258
    [No Abstract]   [Full Text] [Related]  

  • 40. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.